Trans sodium crocetinate/cyclodextrin to increase diffusion of oxygen
Diffusion Pharmaceuticals Inc., a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to
World Biomaterial Congress is going virtual
In light of the COVID-19 global pandemic, the WBC 2020 Organising Committee has decided to cancel the physical 2020 congress.
Repurpusing Famotidine against COVID-19: a Hope or a Hype?
Clinicians and scientists have been studying a number of old existing drugs with the hope of finding therapies they can
Trans sodium crocetinate/cyclodextrin to increase diffusion of oxygen
Diffusion Pharmaceuticals Inc., a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to
Gilead prices remdesivir at 390$/vial for governments
Daniel O’Day, Chairman & CEO, Gilead Sciences posted an open letter yesterday, to share pricing indications for Gilead anti-COVID19 treatment,
Delivering Crocetin across the Blood-Brain Barrier by Using γ-Cyclodextrin to Treat Alzheimer’s Disease
Crocetin (CRT) has shown various neuroprotective effects such as antioxidant activities and the inhibition of amyloid β fibril formation, and
CPHI WORLDWIDE ITALY 2020
The exhibition CPHI Worldwide will be held on October 13-15, 2020 in Fiera Milano, Italy. The CPhI team has been
Summary of currently available drugs which can be potentially used for treatment of COVID-19
The Table below was published in e-book International Pulmonologist’s Consensus On Covid-19 2nd ed 2020 on April 22nd 2020 (ed. Tinku
Gilead to Test a Version of Remdesivir That Can Be Inhaled
The New York Times published on June 22, 2020: The American biopharmaceutical company Gilead Sciences will soon start trials of
Supramolecular polymer bottlebrushes
This review with 427 references focus mainly on the formation of one-dimensional, linear, cylindrical aggregates in solution with pendant polymer
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C